Indian Judge Blocks Bayer's Drug Monopoly Bid

Crippling Dominance of Big Pharma, 

Judge upholds ruling which protects interests of public health over intellectual property

by

Lauren McCauley, staff writer

In a move that advocates are saying is a "momentous" win for public health, an Indian court on Friday rejected a bid from multinational pharmaceutical giant Bayer to block a local generic drug company from mimicking their costly cancer drug.

Bayer had attempted to appeal a 2012 decision by India's patent controller, who had argued the monthly $5,500-per-person cost charged by Bayer for the liver and kidney drug Nexevar was too costly for most Indians. The Hyderabad-based Natco Pharma's version of the drug costs roughly 97% less.

Friday's court's decision highlights India's "critical role" in "balancing intellectual property and public health," Leena Menghaney, South Asia regional head of Medicins San Frontieres (MSF)/ Doctor's Without Borders' regional access campaign, told AFP.

Observers are saying that the decision may have far-reaching impact on the drug market because of India's dominance in the pharmaceutical industry. AFP reports:

India'a Lawyers' Collective, another rights group, said the "momentous" judgement held wide-ranging implications for access to other medicines. 

India's vast generics industry is a major supplier of cheap copycat, life-saving drugs to treat diabetes, cancer and other diseases afflicting people locally and globally who cannot afford expensive branded versions.

This work is licensed under a Creative Commons Attribution-Share Alike 3.0 License'

http://www.commondreams.org/news/2014/12/13/crippling-dominance-big-pharma-indian-judge-blocks-bayers-drug-monopoly-bid